Skip to content

Real-time Opioid Study

Neurofeedback to Reduce Anhedonia and Improve Outcomes in Opioid Use Disorder: a Feasibility Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07768007
Enrollment
3
Registered
2026-08-17
Start date
2026-09-08
Completion date
2027-02-01
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance Use Disorder (SUD)

Brief summary

This feasibility study collects initial data on the use of an fMRI neurofeedback protocol for treating anhedonia in methadone-treated individuals with opioid use disorder (OUD). The intervention tested has previously been shown to reduce anhedonia in individuals with depression and this study is collecting first-in-human data in an OUD population. Investigators will assess tolerability of the intervention and collect preliminary data from 2-3 subjects monitoring changes in anhedonia, non-substance-related autobiographical memory recall, and meaning in life.

Interventions

DEVICEreal-time functional magnetic resonance imaging (rt-fMRI) neurofeedback

A non-invasive, non-pharmacological therapeutic tool that enables an individual to learn to modulate their neural activity in order to effect behavioral change.

Sponsors

Yale University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* ≥3 months of methadone treatment for OUD * Presence of anhedonia, as assessed via SHAPS * Room for improvement in specific autobiographical memory recall, as assessed via AMT

Exclusion criteria

* Failure to pass an MRI screening * Women who are pregnant * Psychosis, as assessed via Yale PRIME Early Psychosis Screening Test * Serious suicidal ideation * Serious medical condition * Legally blind

Design outcomes

Primary

MeasureTime frameDescription
Number of participants who completed the interventionThrough study completion, up to one month post second neurofeedback sessionNumber of participants who completed the full intervention of those enrolled.
Self-report ratings of tolerabilityUp to one month post second neurofeedback sessionQuestionnaire where participants indicate how worthwhile participating in the study was on a 1-7 Likert scale. Total score range 1-7 with higher numbers indicating greater tolerability.

Secondary

MeasureTime frameDescription
Percentage of positive memories recalled as assessed by Autobiographical Memory Test (AMT)Baseline, one week post second neurofeedback session and one month post second neurofeedback sessionA psychological assessment used to measure how specifically an individual can recall positive personal, life-related events.
Changes in anhedonia, as assessed by the Snaith-Hamilton Pleasure Scale (SHAPS)Baseline, one week post second neurofeedback session and one month post second neurofeedback sessionTotal score range 0-14 with higher scores reflecting a higher level of anhedonia (the inability to experience pleasure).

Countries

United States

Contacts

CONTACTSarah Paprotna
sarah.paprotna@yale.edu+1 (203) 737-5994
PRINCIPAL_INVESTIGATORMichelle Hampson, PhD

Yale University

PRINCIPAL_INVESTIGATORKathleen Garrison, PhD

Yale University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 15, 2026